Award Winning Harvard University Diabetes Specialist Appointed To Help Advance Sernova Corp.'s Sertolin Diabetes Therapy To Clinical Trials

KELOWNA, BRITISH COLUMBIA -- (MARKET WIRE) -- January 08, 2007 -- Sernova Corp. (“Sernova”) (TSX VENTURE: SVA) is pleased to announce that Dr. George King, Senior Vice President and Director of Research at Harvard Medical School’s Joslin Diabetes Center, has accepted an appointment to Sernova’s Scientific Advisory Board.

MORE ON THIS TOPIC